Chad Robins, an officer of Adaptive Biotechnologies Corporation, filed a Form 144 notice on November 12, 2026, proposing the sale of 73,221 shares of common stock through Goldman Sachs & Co. LLC on behalf of the Robins Nest Family Foundation.
Key Highlights
- Proposed sale: 73,221 shares of Adaptive Biotechnologies common stock, with an aggregate market value of $2,192,236.74, according to the filing.
- Approximate sale date: November 11, 2026, with the notice dated November 12, 2026, as the filing was unable to be submitted on November 11 due to a federal holiday.
- Shares outstanding: 161,876,694 shares of common stock outstanding as reported in the filing.
- Origin of shares: The 73,221 shares were acquired as Founder's Shares from the issuer on September 1, 2009, with no cash payment noted.
- Recent prior sales: Chad M. Robins sold 321,324 shares on August 17, 2026, for gross proceeds of $7,959,195.48, and 278,676 shares on August 18, 2026, for gross proceeds of $6,844,282.56.
- Selling entity: All shares are to be sold by the Robins Nest Family Foundation, as noted in the filing's remarks.
Robins Nest Family Foundation Proposes Disposition of Founder's Shares in Adaptive Biotechnologies
According to the Form 144 filing submitted to the SEC on November 12, 2026, Chad Robins, identified as an officer of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), intends to sell 73,221 shares of the company's common stock. The filing states the shares are to be sold through Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY 10282, with an approximate sale date of November 11, 2026. The filing notes it was intended for submission on November 11, 2026, but could not be filed due to a federal holiday.
The filing discloses that the 73,221 shares proposed for sale were originally acquired as Founder's Shares directly from Adaptive Biotechnologies Corporation on September 1, 2009, with payment described as "None." The aggregate market value of the shares to be sold is listed as $2,192,236.74. According to the remarks section, all shares in this proposed transaction are to be sold by the Robins Nest Family Foundation.
The filing also details securities sold during the prior three months. Chad M. Robins sold 321,324 shares on August 17, 2026, generating gross proceeds of $7,959,195.48, and an additional 278,676 shares on August 18, 2026, generating gross proceeds of $6,844,282.56. The filing identifies the total shares of common stock outstanding as 161,876,694. The notice was signed by Goldman Sachs & Co. LLC on behalf of Chad Robins.
What Was Disclosed
A Form 144 notice was filed on November 12, 2026, by Chad Robins, an officer of Adaptive Biotechnologies Corporation, proposing the sale of 73,221 Founder's Shares on behalf of the Robins Nest Family Foundation, with an aggregate market value of $2,192,236.74.



Please wait processing your request...